LUPIN stock news on Anadi Algo News

Sunday, March 15, 2026
DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|
AnadiAlgoNews
सट्टा नहीं, सिस्टम
Stock Landing|3 matching stories

LUPIN Stock News, Sentiment & Trading Insights

Latest AI-analyzed news for LUPIN, including sentiment, related articles, and market-moving coverage.

Top Story|et_companiesabout 11 hours ago

Kathua to become India’s antibiotic powerhouse with Rs 600 crore pharma facility

The Indian pharma sector is actively working to reduce its reliance on imported APIs, especially from China. This investment aligns with the government's 'Make in India' push and Production Linked Incentive (PLI) schemes for pharmaceuticals.

buy
Bullish+6590%
PharmaceuticalsChemicals
+65

Impact Score

Affected Stocks

AUROPHARMAAurobindo Pharma Ltd.
Positive
DIVISLABDivi's Laboratories Ltd.
Positive
GRANULESGranules India Ltd.
Positive
LUPINLupin Ltd.
Positive
Look for opportunities in API-focused pharma companies, as this development signals continued government support and potential for domestic growth, with a bias towards long positions.
livemint_markets2 days ago

Stocks to buy or sell: From Lupin to NTPC— Ajit Mishra of Religare Broking suggests strategies for these 3 shares

In a declining market, specific stock recommendations from analysts can help identify potential outperformers or defensive plays.

buy
Bullish+44.680%
5 factsLUPINNTPC
Look for entry points in Lupin and NTPC, potentially using the analyst's suggested strategies, while being mindful of overall market sentiment.|Quick check: LUPIN bullish bias (overbought), NTPC bullish bias (+3.2% 1d).
livemint_companies4 days ago

Ozempic's drug maker, Novo Nordisk, receives FDA warning letter over unreported side effects: What are they?

Increased regulatory scrutiny by the US FDA on global pharma companies can set a precedent for stricter compliance, potentially impacting Indian pharma companies with US market exposure.

buy
Bullish+18.770%
5 factsLUPINDRREDDY
Neutral for Indian pharma; however, any news of increased FDA oversight could create short-term volatility for companies with significant US revenue.|Quick check: LUPIN bullish bias (+2.0% 1d), DRREDDY bullish bias (+2.3% 1d).